A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Inclusion Criteria:

• Age ≥18 years at time of signing Informed Consent Form

• Documented diagnosis of diabetes mellitus (Type 1 or Type 2)

• HbA1c level of ≤12% within 2 months prior to screening or at screening

Inclusion Criteria for Study Eye

• Moderately severe or severe NPDR (ETDRS-DRSS level 47 or 53)

• BCVA score of ≥ 69 letters (20/40 approximate Snellen equivalent or better)

Exclusion Criteria:

• Uncontrolled blood pressure

• Cerebrovascular accident or myocardial infarction within 6 months prior torandomization

• Atrial fibrillation diagnosis or worsening within 6 months prior to randomization

• Current systemic treatment for a confirmed active systemic infection

• Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis, oranticipated to require hemodialysis or peritoneal dialysis at any time during thestudy

• History of other disease, other non-diabetic metabolic dysfunction, physicalexamination finding, or clinical laboratory finding giving reasonable suspicion of acondition that contraindicates the use of ranibizumab or surgical placement of thePDS implant; that might affect interpretation of the results of the study; or thatrenders the patient at high risk for treatment complications in the opinion of theinvestigator or Sponsor

Ocular Exclusion Criteria for Study Eye:

• Presence of center-involved diabetic macular edema (defined as CST ≥325 µm)

• Any intravitreal anti-VEGF treatment at any time prior to randomization

• Any use of medicated intraocular implants, including Ozurdex® or Iluvien® implantsat any time prior to randomization

• Any intravitreal corticosteroid treatment at any time prior to randomization

• Any periocular (e.g., subtenon) corticosteroid treatment at any time prior torandomization

• Any PRP at any time prior to randomization

• Any macular laser photocoagulation (such as micropulse and focal or grid laser) atany time prior to randomization

• Active intraocular inflammation (grade trace or above)

• Clinically significant abnormalities of the vitreous-retinal interface involving themacular area or disrupting the macular architecture, such as vitreous-retinaltraction or epiretinal membrane (assessed by the investigator and confirmed by thecentral reading center)

• Uncontrolled ocular hypertension or glaucoma and any such condition the investigatordetermines may require a glaucoma-filtering surgery during a participant'sparticipation in the study

• History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucomasurgery

• Any concurrent ocular condition (e.g., cataract, epiretinal membrane) that wouldrequire surgical intervention during the study to prevent or treat visual loss thatmight result from that condition

• Any concurrent ocular condition (e.g., amblyopia, strabismus) that may affectinterpretation of study results

• History of other ocular diseases that gives reasonable suspicion of a disease orcondition that contraindicates the use of ranibizumab, that might affectinterpretation of study results, or that renders the participant at high risk fortreatment complications

Ocular Exclusion Criteria for Either Eye

• Suspected or active ocular or periocular infection of either eye

• Any history uveitis including idiopathic, drug-associated or autoimmune-associateduveitis